Back to journals
Academic JournalOpen Access

Neuropsychiatric Disease And Treatment

6 Papers Indexed in Blossom

Data updated

Research Footprint

Neuropsychiatric Disease And Treatment has 6 tracked papers indexed in Blossom (2013–2023) from 33 authors, most often covering Ketamine, Psilocybin and Esketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

Published Papers

Open Accessindividual

Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis

This re-analysis of a Phase I randomised controlled trial (n=89) investigated predictors of mystical and challenging experiences in healthy volunteers receiving psilocybin. It finds that dosage was the strongest predictor of intensity for both experience types, while older age was associated with fewer challenging experiences and neuroticism correlated with challenging experiences only at the higher dose.

Published
Journal
Neuropsychiatric Disease And Treatment
Authors
Carter, B., Cleare, A. J., Rucker, J., Ko, K.
Open Accessmeta

Ketamine in Bipolar Disorder: A Review

This review (2020) investigates the potential of ketamine for the treatment of bipolar disorder (BD). Although studies with BD and ketamine are limited, studies on (unipolar) depression and neurological effects of ketamine (e.g. BDNF levels) show positive signals.

Published
Journal
Neuropsychiatric Disease And Treatment
Authors
Wilkowska, A., Szałach, L., Cubała, W. J.
Open Accessmeta

Management of treatment-resistant depression: Challenges and strategies

This review (2020) details the background and therapeutic challenges associated with treatment-resistant depression. A wide range of treatments are evaluated, including novel therapeutics such as ketamine and psilocybin.

Published
Journal
Neuropsychiatric Disease And Treatment
Authors
Voineskos, D., Daskalakis, Z. J., Blumberger, D. M.
Open Accessmeta

Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review

This retrospective chart review (n=27) investigates the efficacy and safety of rapid infusion of esketamine in patients with treatment-resistant depression (TRD) and bipolar depression (BD). The study found that rapid infusion of esketamine is not the best choice for treatment-resistant depression due to tolerability issues. Additionally, patients reported dissociative symptoms ranging from mild to severe and found them to be disturbing.

Published
Journal
Neuropsychiatric Disease And Treatment
Authors
Correia-Melo, F. S., Argolo, F. C., Araújo-de-Freitas, L., Leal, G. C., Kapczinski, F., Lacerda, A. L. T., Quarantini, L. C.
Open Accessmeta

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies

This meta-analysis (2016, 9 RCT studies, n=368) suggests ketamine is an effective short-term treatment for major depressive disorder (MDD).

Published
Journal
Neuropsychiatric Disease And Treatment
Authors
Han, Y., Chen, J., Zou, D., Zheng, P., Wang, H., Zhou, X., Zhang, Y., Liu, Y., Li, P., Li, Q.
Open Accessindividual

Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression

This double-blind, cross-over, placebo-controlled study (n=27) investigated the antidepressant and psychotomimetic effects of a single ketamine infusion (38mg/70kg) in patients diagnosed with major depressive disorder (MDD). Ketamine infusion induced acute psychotomimetic symptoms, which correlated with alleviating negative mood ratings and improving depression symptoms in the days after.

Published
Journal
Neuropsychiatric Disease And Treatment
Authors
Sos, P., Klirova, M., Novák, T., Kohutova, B., Horacek, J., Páleníček, T.

Quick Facts

Papers Indexed
6
h-Index
98
Open Access
Yes
Publisher
Taylor & Francis
Country
New Zealand
Website
Visit